In translational clinical studies, gastric cancers with high-level clonal FGFR2 amplification have also been shown to respond better to treatment with selective FGFR tyrosine kinase inhibitors, whereas cancers with low-level amplification did not respond [8, 9]. This evidence concerns the gene FGFR2 and gastric cancer.